NIKKEI 225
38,073.98 -128.39 (-0.34%) HANG SENG
18,489.81 +175.95 (+0.96%) CRUDE OIL
79.39 +0.40 (+0.51%) GOLD FUTURES
2,322.80 +0.50 (+0.02%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,388.48 -622.27 (-1.24%)
Supernus Pharmaceuticals, Inc. (0LB2.L)
| Previous close | 30.57 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 83 |
| Market cap | 13.896M |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | 0.24 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- Zacks
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Supernus (SUPN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
- Benzinga
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor fluctuations (“off” episodes) in Parkinson’s disease (PD). The FDA has issued a Complete Response Letter (CRL) in response to the company’s New Drug Application (NDA) for SPN-830. The CRL indicates that the review cycle for the application is complete but that the application still needs to be prepa
